CardioMech AS is a privately-held Norwegian company that develops an innovative technology...
Continue Reading-
GESYNTA PHARMA
Gesynta Pharma is a privately held Swedish company located in Stockholm...
Continue Reading -
CardioMech AS Announces $18.5M Series A for its Transcatheter Mitral Valve Repair Technology
CardioMech AS Announces $18.5M Series A...
Continue Reading -
Abliva receives positive FDA feedback on its KL1333 development plan
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it has received positive feedback from the…
Continue Reading -
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss
PIPE-505 is the first small molecule developed specifically for the treatment of sensorineural hearing loss…
Continue Reading -
Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis
July 7, 2020, Stockholm Gesynta Pharma AB (‘Gesynta’ or ‘The Company’) a clinical-stage company…
Continue Reading -
€1.9M EU funding takes Nelli® available for all epilepsy patients
Neuro Event Labs (NEL) will use €1.9M EU Horizon 2020 grant to become the standard…
Continue Reading -
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
On April 22, 2020, the Board of Directors of Abliva AB (publ) (“Abliva” or the…
Continue Reading -
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round Investment Q2…
Continue Reading
